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OBJECTIVE — While women with prior gestational diabetes mellitus (GDM) are more likely
todisplayfeaturesofthemetabolicsyndrome,includinghypertension,intheyearsafterdelivery,
it is unclear whether these components are also present before pregnancy. We examined the
relationship between blood pressure (BP) measured before and during early pregnancy (20
weeks) and the risk of GDM in a nested case-control study.
RESEARCH DESIGN AND METHODS — Case (n  381) and control (n  942)
subjects were selected from a cohort of women delivering between 1996 and 1998 and screened
for GDM between 24 and 28 weeks’ gestation. GDM was deﬁned by the National Diabetes Data
Group criteria. BP and covariates data were obtained by review of the medical records. Women
were categorized according to BP levels recommended by the American Heart Association out-
side of pregnancy: 120/80 mmHg (normal), 120–139/80–89 mmHg (prehypertension), and
140 and/or 90 mmHg or use of antihypertensive medications (hypertension).
RESULTS — Duringearlypregnancy,womenwithprehypertensionhadasmallincreasedrisk
of GDM (odds ratio [OR] 1.56 [95% CI 1.16–2.10]), and women with hypertension had a
twofold increased risk of GDM (2.04 [1.14–3.65]) compared with women with normal BP after
adjusting for age, race/ethnicity, gestational week of BP, BMI, and parity. Similar results were
seen among the subset of women with BP levels measured before pregnancy (1.44 [0.95–2.19]
for prehypertension and 2.01 [1.01–3.99] for hypertension).
CONCLUSIONS — Clinicians should be aware that women presenting with hypertension
may warrant early screening or intervention to prevent GDM.
Diabetes Care 31:2362–2367, 2008
T
ype 2 diabetes and hypertension are
both components of the metabolic
syndrome and commonly occur to-
gether in individuals. A recent study of
initially healthy middle-aged women
found that blood pressure (BP) predicted
thedevelopmentofincidenttype2diabe-
tes independent of BMI and other known
diabetes risk factors (1). Several studies
have shown that women with a history of
gestational diabetes mellitus (GDM) are
more likely to have features of the meta-
bolic syndrome, including high BP, in the
years after delivery (2–5). It is unclear
whether elevated BP before or during
early pregnancy is associated with the de-
velopment of GDM.
Crowther et al. (6) showed that treat-
ment of mild-to-moderate levels of glu-
cose intolerance in midpregnancy
effectively reduced both perinatal and
maternal complications. Therefore, iden-
tifying additional variables that predict
the development of GDM may help iden-
tify women who would beneﬁt from early
screening and, if needed, early treatment
of pregnancy hyperglycemia to prevent
perinatal complications. Because BP is a
vitalsignthatismeasuredateachmedical
visit, it would be an easy and inexpensive
clinical characteristic that could be used
to identify women at risk of GDM. We
therefore evaluated the relationship be-
tween BP before and during early preg-
nancy (20 weeks’ gestation) and risk of
GDM in a nested case-control study
among women who delivered singleton
live infants at a large U.S. group practice
prepaid health plan and received uniform
screening and a standardized diagnostic
test for GDM.
RESEARCH DESIGN AND
METHODS
Setting
The study setting was the Kaiser Perma-
nente Medical Care Program of Northern
California (KPMCP-NC), which at the
time provided comprehensive medical
services through 15 hospitals and 23
outpatient clinics to over 3 million mem-
bers located in a 14-county region in
northern California. The KPMCP-NC
membershiprepresents30%ofthesur-
rounding population, and it is represen-
tative of the population living in the same
geographic area demographically, ethni-
cally, and socioeconomically, except
that the KPMCP-NC membership under-
represents the very poor and the very
wealthy (7).
Cohort identiﬁcation
The methods used to identify this cohort
have been described in detail elsewhere
(8). Brieﬂy, we identiﬁed all pregnancies
that resulted in a singleton live birth be-
tween 1 January 1996 and 30 June 1998
amongwomenwithoutrecognizeddiabe-
tes before the index pregnancy. All preg-
nancies resulting in a singleton live birth,
screenedforGDMbetween24–28weeks’
gestation, and without a diagnosis of
GDMinapriorpregnancywereeligibleto
be selected for this study (Fig. 1). Brieﬂy,
wehad46,727singletonpregnanciesthat
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according to the earliest ultrasound. All
437 GDM case subjects (according to the
NDDG criteria) that had been in the
health plan for at least 5 years were se-
lected for medical chart review, and 388
were included in the study. A total of
1,000 control subjects were randomly se-
lected among 45,245 pregnancies with
normoglycemia; 972 met the eligibility
criteria after medical chart review, and
29% were members of the health plan for
at least 5 years and served as control sub-
jects for the subanalyses on “prepreg-
nancy” BP levels and risk of GDM.
Medical chart review
Trained medical records abstractors com-
pleted chart review on the selected case
and control subjects and conﬁrmed if cri-
teria for inclusion were met and if any of
the exclusion criteria were present.
Case deﬁnition
Women were classiﬁed as having GDM at
the index pregnancy if two or more of the
four plasma glucose values obtained dur-
ing the 100-g 3-h OGTT were abnormal
according to the NDDG criteria (9): fast-
ing 105 mg/dl (5.8 mmol/l), 1 h 190
mg/dl (10.5 mmol/l), 2 h 165 mg/dl
(9.1 mmol/l), and 3 h 145 mg/dl (8.0
mmol/l). All plasma glucose measure-
ments were performed using the hexoki-
nase method by the regional laboratory of
Kaiser Permanente Northern California.
ThislaboratoryparticipatesintheCollege
of American Pathologists’ accreditation
and monitoring program.
Data collection
Trained medical chart abstractors re-
viewed all available medical records to
obtain information on subjects’ measured
BPbeforeandduringearlypregnancyand
potential confounders. Abstractors re-
corded the ﬁrst BP measured during a
prenatal visit provided it was performed
before 20 weeks’ gestation, according to
the earliest ultrasound. For pregravid BP,
the BP measured closest to but before the
last menstrual period and no more than 5
yearsbeforepregnancywasrecorded.The
BP measured before pregnancy was not
recorded if it was from an emergency or
urgent-care visit. Information on use of
BP medications was obtained from the
medical chart.
Other information obtained on po-
tential confounders during the medical
record review included any body weights
measuredbeforepregnancyinanonpreg-
nant state. Last menstrual period before
the index pregnancy, gestational week at
the earliest ultrasound used to calculate
gestational age at screening for GDM,
marital status, family history of diabetes,
family history of hypertension, self-
reported prepregnancy weight, weight at
ﬁrstprenatalvisit,parity,andheightwere
abstracted from the prenatal form com-
pleted at the ﬁrst prenatal visit. Prepreg-
nancy weight was deﬁned as the last
recordedweightfoundinthechartbefore
the woman’s last menstrual period for the
index pregnancy. For the 14.4% of
women for whom these data were not
available, the self-reported prepregnancy
weight on the prenatal form was used.
Prepregnancy BMI was calculated as
prepregnancy weight in kilograms di-
vided by the square of height in meters.
BMIatﬁrstprenatalvisitwascalculatedas
weightinkilogramsmeasuredatﬁrstpre-
natal visit divided by the square of height
in meters. Women’s self-reported race/
ethnicity and education were obtained by
linkage to the electronic birth certiﬁcate
database. Gestational age at ﬁrst prenatal
visit with a BP measurement was calcu-
lated from the earliest ultrasound per-
formed before 24 weeks’ gestation.
Figure 1—GCT, glucose challenge test; NDDG, National Institute of Diabetes and Digestive and
Kidney Diseases.
Hedderson and Ferrara
DIABETES CARE, VOLUME 31, NUMBER 12, DECEMBER 2008 2363Exposure deﬁnition
For both prepregnancy BP and BP at ﬁrst
prenatal visit, women were classiﬁed into
three predeﬁned BP categories according
the American Heart Association’s criteria:
120 mmHg for systolic and 80
mmHg for diastolic BP (subsequently call
normal BP), 120–139 mmHg for systolic
and/or 80–89 mmHg for diastolic (sub-
sequently called prehypertension), and at
least 140 mmHg for systolic or at least 90
mmHg for diastolic or a prescription for
antihypertensive treatment found in the
medicalchart(subsequentlyreferredtoas
hypertension) (10).
Missing data
Women for whom information on either
early pregnancy or prepregnancy BP was
unavailable were excluded from that par-
ticular analysis. BP measured during the
ﬁrst prenatal visit was missing for 7
(1.8%) case subjects and 30 (3.1%) con-
trol subjects.
BP before pregnancy was not ab-
stracted for 185 of the control subjects.
Amongcaseandcontrolsubjectswhohad
BP before pregnancy abstracted, these
data were missing for 6 (1.5%) case sub-
jects and 186 (23.6%) control subjects.
Information on BP before pregnancy was
missing for a larger proportion of control
subjects in part because the question was
not initially included on the question-
naire at the beginning of the study (11)
that provided data on control subjects.
A total of 381 case subjects and 942
control subjects remained for the analysis
of early pregnancy BP, and 381 case sub-
jects and 289 control subjects remained
for the subanalysis of prepregnancy BP.
Statistical methods
Unconditional logistic regression was
used to obtain odds ratios (ORs) as esti-
mates of the relative risk of GDM in rela-
tion to category of BP. Women with
normal BP were used as the reference
group.Toassessconfounding,weentered
covariates into a logistic regression model
one at a time and then compared the ad-
justed and unadjusted odds ratios (12).
Final logistic regression models included
covariates that altered unadjusted odds
ratios for BP by at least 10% as well as
those covariates of a priori interest (i.e.,
parity).Variablesevaluatedforconfound-
ingwerematernalage,race/ethnicity,pre-
gravid BMI (kilograms divided by the
square of height in meters), parity, mater-
nal education in years, family history of
diabetes (yes/no), and family history of
hypertension (yes/no). BMI at ﬁrst prena-
tal visit when the BP was measured and
gestationalweekatBPmeasurementwere
also included in the adjusted model as-
sessing BP during early pregnancy. For
the analysis of BP before pregnancy and
GDM, we adjusted for prepregnancy BMI
and time between BP measurement and
pregnancy. To assess the potential modi-
fying effects of BMI (overweight 25
Table 1—Selected characteristics of case and control subjects
GDM case
subjects* Control subjects
n 381 942
Age (years)
25 26 (6.8) 229 (24.3)
25–29 52 (13.6) 226 (24.0)
30–34 132 (34.6) 303 (32.2)
35 171 (44.9) 184 (19.5)
Race/ethnicity
Non-Hispanic white 168 (44.1) 502 (53.3)
Hispanic 75 (19.7) 166 (17.6)
Asian 47 (12.3) 82 (8.7)
African American 29 (7.6) 90 (9.6)
Other 58 (15.2) 99 (10.5)
Unknown 4 (1.0) 3 (0.3)
Marital status
Never married 54 (14.2) 226 (24.0)
Married 300 (78.7) 689 (73.1)
Widowed, divorced, or separated 16 (4.2) 21 (2.2)
Unknown 11 (2.9) 6 (0.6)
Education (years)
12 142 (37.3) 392 (41.6)
13–15 124 (32.5) 267 (28.3)
16 73 (19.2) 159 (16.9)
17 37 (9.7) 115 (12.2)
Unknown 5 (1.3) 9 (1.0)
Parity
0 148 (38.8) 405 (43.0)
1 125 (32.8) 343 (36.4)
2 108 (28.3) 194 (20.6)
Family history of diabetes
First-degree relative 87 (22.8) 104 (11.0)
Second-degree relative 98 (25.7) 204 (21.7)
None 154 (40.4) 561 (59.6)
Unknown 42 (11.0) 73 (7.7)
Family history of hypertension
First-degree relative 113 (29.7) 233 (24.7)
Second-degree relative 41 (10.8) 100 (10.6)
None 168 (44.1) 532 (56.5)
Unknown 59 (15.5) 77 (8.2)
BMI at ﬁrst prenatal visit (kg/m
2)
20 14 (3.7) 98 (10.4)
20.1–24.9 96 (25.2) 423 (44.9)
25.0–29.9 126 (33.1) 250 (26.5)
30 142 (37.3) 149.0 (15.8)
Unknown 3 (0.8) 22.0 (2.3)
Blood pressure during pregnancy
Normal 197 (51.7) 668 (70.9)
Prehypertenison 147 (38.6) 240 (25.5)
Hypertension 37 (9.7) 34 (3.6)
Data are n (%). *GDM equals NDDG criteria. Normal BP: 120/80 mmHg; prehypertension: 120–139/
80–89 mmHg; and hypertension: 140 and/or 90 mmHg or use of antihypertensive drugs.
High blood pressure and GDM risk
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2 vs. not overweight 25 kg/m
2),
age(30vs.30years),familyhistoryof
diabetes (ﬁrst- or second-degree versus
none), parity (one or more live births vs.
none), and race/ethnicity (non-Hispanic
white vs. African American, Asian, and
Hispanic women), we examined interac-
tion terms and repeated analyses with-
in these subgroups. This study was
approvedbythehumansubjectscommit-
tee of the Kaiser Foundation Research
Institute.
RESULTS— Characteristicsofwomen
with GDM and control subjects are pre-
sented in Table 1. Women with GDM
weremorelikelytobeHispanic,Asian,or
from other nonwhite racial groups; to be
older than 35 years; to have 12 years of
education; to have a family history of di-
abetes; to have two or more prior live-
births; and to be overweight or obese at
the ﬁrst prenatal visit. GDM case subjects
were also more likely to have hyperten-
sion or prehypertension both before and
early in pregnancy. Mean gestational age
at ﬁrst BP measurement was 11.5 weeks
for case subjects and 11.7 weeks for con-
trol subjects. Pregravid BP was measured
on average 9.7  12.3 months (mean 
SD)beforethewoman’slastmenstrualpe-
riod for case subjects and 8.1  8.5
months for control subjects.
After adjustment for age, race/
ethnicity, parity, BMI, family history of
diabetes, and gestational age at BP mea-
surement, GDM risk increased among
women with prehypertension and to a
stronger degree among women with hy-
pertension during early pregnancy (OR
1.41 [95% CI 1.04–1.90] and 2.08
[1.17–3.69], respectively) (Table 2). We
examined the interaction terms between
covariates presented in Table 2 and BP in
the association with GDM risk; however,
none of the interaction terms were statis-
tically signiﬁcant and the P values ranged
from 0.25 for age and BMI to 0.91 for
family history of diabetes. We also reran
the analysis after excluding 11 case sub-
jectsand8controlsubjectswhoweretak-
ingantihypertensivemedications,andthe
associations did not change signiﬁcantly.
Stratiﬁed analyses suggested that the
association between elevated early preg-
nancy BP and GDM was stronger among
womenknowntobeathighriskforGDM.
Women who were overweight or obese
(BMI 25.0 kg/m
2) before pregnancy
presenting with hypertension during the
ﬁrst trimester of pregnancy had an almost
threefold increased risk of developing
GDM (OR 2.76 [95% CI 1.46–5.23]),
whereas the corresponding OR for
women who were not overweight was
1.26 (95% CI 0.35–4.35).
In the subsample of women who had
been members of KPMCP-NC for 5 years
before pregnancy and with information
on BP before pregnancy and smoking sta-
tus, GDM risk was associated with an in-
creased risk among women with
prehypertension and hypertension, and
the magnitude of the association was sim-
ilar to that found with BP during preg-
nancy (Table 3).
We also reran the analysis after ex-
cluding 11 case subjects and 8 control
subjects who took antihypertensive med-
ications before pregnancy, and the asso-
ciations did not change.
CONCLUSIONS— In this study,
women with hypertension either during
the 5 years before pregnancy or during
theﬁrsttrimesterofpregnancyhadatwo-
fold increased risk of developing GDM
during pregnancy. While attenuated,
these associations persisted after adjust-
ing for BMI, suggesting that the associa-
tion is independent of BMI. However, the
association between BP and GDM was
stronger among women who were over-
weight (BMI 25.0 kg/m
2).
Arecentstudyamonginitiallyhealthy
women found high BP was associated
with a twofold increased risk of develop-
ing type 2 diabetes during 4 years of
follow-up after adjusting for known pre-
dictors of diabetes (1). Data on BP before
or during pregnancy in relation to the oc-
currence of GDM are sparse. Our results
are generally consistent with the one pre-
vious study of BP and risk of GDM (13).
Lao and Ho (13) examined ﬁrst-trimester
BP and risk of GDM among 131 high-risk
Chinese women and found that systolic
BP above the median (109 mmHg) had a
fourfold increased risk of GDM (OR 4.20
[95% CI 1.97–8.94]). While the magni-
tude of the association they found was
greater than our ﬁndings, they examined
only high-risk women referred to a clinic
providing antenatal care, categorized
women according to a dichotomous cut-
Table 2—ORs and 95% CI for GDM associated with GDM risk factors and BP during the ﬁrst
prenatal visit
Case subjects Control subjects
Crude OR
(95% CI)
Adjusted OR*
(95% CI)
n 381 942
Blood pressure
Normal 197 (51.7) 668 (70.9) 1.00 1.00
Prehypertension 147 (38.6) 240 (25.5) 2.08 (1.60–2.60) 1.56 (1.16–2.10)
Hypertension 37 (9.7) 34 (3.6) 3.69 (2.26–6.04) 2.04 (1.14–3.65)
Age 30 years 308 (79.4) 502 (51.7) 3.54 (2.57–4.88)
BMI 25 kg/m
2 276 (56.4) 426 (44.7) 2.43 (1.82–3.25)
Nonwhite 219 (56.4) 458 (47.1) 1.77 (1.34–2.34)
First- or second-
degree relative
with diabetes
189 (54.7) 320 (35.7) 1.73 (1.32–2.28)
1 live births 238 (61.3) 556 (57.2) 0.77 (0.57–1.04)
Data are n (%) unless otherwise indicated. *ORs from multivariate model adjusted for age, BMI at ﬁrst
prenatal visit, race/ethnicity, family history of diabetes, parity, and gestational week at BP measurement.
Table 3—ORs and 95% CI for GDM associated with BP before pregnancy
Case subjects Control subjects
Crude OR
(95% CI)
Adjusted OR*
(95% CI)
n 381 289
Blood pressure
Normal 152 (39.9) 329 (54.7) 1.00 1.00
Prehypertension 181 (47.5) 230 (38.3) 1.66 (1.20–2.30) 1.44 (0.95–2.19)
Hypertension 48 (12.6) 42 (7.0) 2.18 (1.26–3.79) 2.01 (1.01–3.99)
Data are n (%) unless otherwise indicated. Data are from the subset of women who were members of KPNC
5 years before pregnancy. *Adjusted for age, race/ethnicity, prepregnancy BMI, parity, smoking status,
family history of diabetes, and time between BP measurement and pregnancy.
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mation on confounders.
This study is the ﬁrst to our knowl-
edge to examine BP and GDM in an eth-
nically diverse population of women who
underwent uniform screening for GDM.
This study has several strengths, includ-
ing the ability to assess measured BPs ob-
tainedpregravidandriskofGDM.Aclear
deﬁnitionofGDMwasbasedonobjective
measures of pregnancy glycemia among a
cohort with universal screening per-
formed at 24–28 weeks’ gestation. Given
the extensive chart review, we were also
able to identify and exclude women with
recognized preexisting diabetes before
pregnancy. Finally, we were able to con-
trol for several important potential con-
founding factors.
This study also has several limita-
tions. During normal pregnancy, BP
steadily decreases up to 21 weeks’ gesta-
tionandthenincreasesduringthesecond
half of pregnancy (14). Our assessment of
hypertension during pregnancy probably
only captured severe case subjects in
whom BP remained elevated even during
early pregnancy. Other limitations of this
study include the reliance on a single
measure of BP, which may be inﬂuenced
by external and internal stimuli, such as
physical activity, diet, and emotional
state. For the main analysis, we lacked
information on smoking, a potential con-
founder; however, in a subanalysis lim-
ited to women who were members of the
health plan for 5 years before pregnancy,
we had smoking history and it did not
confoundtheassociation.Fortheanalysis
of pregravid BP and GDM, we were miss-
ing information on BP on a large portion
of control subjects; however, the magni-
tude of the association between early
pregnancy BP and GDM was similar and
had very little missing data. Use of certain
types of antihypertensive medications
may be associated with risk of type diabe-
tes (15); however, sensitivity analyses ex-
cluding the small number of women who
used antihypertensive drugs pregravid
did not change our results.
Several studies have examined the
metabolic syndrome or its components
2–11 years after pregnancy, and in most
of these studies, mean BP levels were sig-
niﬁcantly higher among the women with
prior GDM compared with women who
had normal glycemia during pregnancy
(3–5,16). We found the association be-
tween high BP and GDM was stronger
among overweight or obese women, sug-
gesting that these two components of the
metabolic syndrome may interact syner-
gisticallytoproduceadversemetabolicef-
fects that predispose to GDM during
pregnancy.
There are several common patho-
genic pathways to hypertension and
GDM that may be underlying the associ-
ationbetweenthetwoconditions.Insulin
resistancehasbeenshowntobeacontrib-
uting factor to both chronic (17) and ges-
tational hypertension (18), and it is
known to be involved in the pathogenesis
of GDM (19). Endothethial dysfunction
hasbeenfoundinwomenwithGDMboth
during (20) and after (21) pregnancy and
is also closely related to hypertension
(22). Finally, markers of inﬂammation
such as C-reactive protein have been as-
sociated with increased BP levels (23),
and elevated early pregnancy CRP levels
have been related to increased risk of
GDM (24).
In summary, our data suggest that
women presenting with high BP, espe-
cially those who are overweight, are at in-
creased risk of developing GDM during
pregnancy. Clinicians should be aware
thatthissubgroupofwomenmaywarrant
the initiation of early screening or dietary
and exercise interventions to prevent the
development of GDM.
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